Skip to main content

Site notifications

Ozempic (semaglutide) shortage collection

There is a worldwide shortage of this diabetes medicine. TGA alerts relate to the shortage in Australia.

Increased global demand for semaglutide products is impacting availability of Ozempic (semaglutide) in Australia. Alerts on the shortage of Trulicity (dulaglutide) and Mounjaro (tirzepatide) are also accessible from this collection.

Read current information and updates at:

The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply throughout 2025 will be limited.

Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.

Collection content

15 result(s) found, displaying 1 to 10
  • Consumers and health professionals should be aware that counterfeit Ozempic-labelled pens have been imported into Australia. These pens may pose a serious health risk and should not be used. There are clear inconsistencies from the original product to look out for.
  • Pharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.
  • We are aware of an emerging trend for telehealth providers to offer compounded semaglutide-like products. Compounded semaglutide-like products are ‘unapproved’ therapeutic goods and have not been evaluated by us for safety, quality and efficacy.
  • The availability of all strengths of Mounjaro (tirzepatide) will be limited until 31 August 2024, due to unexpected high demand. Patients and healthcare professionals should check the Medicine Shortage Reports Database for the latest supply information.
  • The supply of Ozempic (semaglutide) in Australia is improving however the shortage continues. Stay updated about how the shortage impacts you.
  • The TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.

Help us improve the Therapeutic Goods Administration site